相似文献
1
Short-term Safety of Dimethyl Fumarate for Psoriasis in Korea.
Ann Dermatol. 2024 Aug;36(4):252-254. doi: 10.5021/ad.23.054.
2
Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.
Wien Klin Wochenschr. 2019 Oct;131(19-20):485-492. doi: 10.1007/s00508-019-01551-6. Epub 2019 Oct 7.
3
The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway.
Front Med (Lausanne). 2022 Feb 8;9:760852. doi: 10.3389/fmed.2022.760852. eCollection 2022.
4
Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis.
Dermatol Ther. 2020 Nov;33(6):e13943. doi: 10.1111/dth.13943. Epub 2020 Jul 14.
5
Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.
Drugs. 2018 Jan;78(1):123-130. doi: 10.1007/s40265-017-0854-6.
6
A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.
Expert Opin Drug Saf. 2020 Apr;19(4):373-380. doi: 10.1080/14740338.2020.1736553. Epub 2020 Mar 11.
7
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Arch Dermatol Res. 2018 Aug;310(6):475-483. doi: 10.1007/s00403-018-1825-9. Epub 2018 Mar 24.
8
Dimethyl fumarate for psoriasis.
Drug Ther Bull. 2017 Dec;55(12):141-144. doi: 10.1136/dtb.2017.12.0565.
9
10
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.
本文引用的文献
1
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study.
J Clin Med. 2022 Aug 16;11(16):4778. doi: 10.3390/jcm11164778.
2
Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience.
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e534-e537. doi: 10.1111/jdv.17997. Epub 2022 Feb 25.
3
Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
Dermatol Ther (Heidelb). 2021 Dec;11(6):1965-1998. doi: 10.1007/s13555-021-00602-z. Epub 2021 Sep 22.
4
Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study.
Dermatol Ther. 2021 Sep;34(5):e15066. doi: 10.1111/dth.15066. Epub 2021 Aug 2.
5
Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis.
Drugs Context. 2021 May 31;10. doi: 10.7573/dic.2020-12-4. eCollection 2021.
6
No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.
Pharmacol Res Perspect. 2019 Dec 2;7(6):e00540. doi: 10.1002/prp2.540. eCollection 2019 Dec.
7
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.
8
Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
CNS Drugs. 2018 Sep;32(9):813-826. doi: 10.1007/s40263-018-0541-5.
9
Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1710-1727. doi: 10.1111/jdv.15019. Epub 2018 May 18.
10
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm - and placebo-controlled trial (BRIDGE).
Br J Dermatol. 2017 Mar;176(3):615-623. doi: 10.1111/bjd.14947. Epub 2016 Nov 15.
Zotero 插件